| Ytd | -88.51% | |
| 1y | -97.75% |
| Open | 3.44 | Prev Close | 3.48 | Low | 3.37 | High | 3.44 | Mkt Cap | 64.28K |
| Vol | 10.57K | Avg Vol | 86.56K | EPS | -393.10 | P/E | -0.01 | Forward P/E | N/A |
| Beta | 1.66 | Short Ratio | 0.08 | Inst. Own | 37.09% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 3.21 | 200-d Avg | 23.74 | 1yr Est | 0.00 |
PBM News
MINNEAPOLIS--(BUSINESS WIRE)--Tredium Solutions, a provider of pharmacy benefit management (PBM) tec
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or th
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2026) - Pacific Bay Minerals Ltd. (TSXV: PBM)
https://www.hhs.gov/press-room/fda-accelerates-action-treatments-serious-mental-illness-following-ex
Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate
Psyence Biomedical (NASDAQ: PBM) stock is surging Monday on a broad psychedelic rally and a company-
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed"
TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $1
US stocks rise, Dow gains 600 points. NASDAQ up 1.05% and S&P 500 up 0.74%. Energy stocks down 4
Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourc
Blaize Holdings rose 24.3% in pre-market trading on $50M contract with NeoTensr & MOU with Winma
https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/
Calgary, Alberta – TheNewswire - April 14, 2026 – Aurwest Resources Corporation (“ Aurwest ” or the
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed”
Psyence Biomedical (NASDAQ: PBM - Get Free Report) and XBiotech (NASDAQ: XBIT - Get Free Report) are
“The strongest companies are built on the right foundations long before their moment arrives,” says
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed”
NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed”
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed”
The Put Option Agreement positions Psyence BioMed for potential significant future equity participat
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed"
NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed”
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed”
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed”